Cancer Knowledge Network: What Factors are Associated with Hearing Loss in Childhood Cancer Survivors Treated with Platinum Agents?

THE RESEARCH:  Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer:  A DCOG late-effects study.  Researchers compiled treatment data and audiograms from 451 childhood cancer survivors (CCS) treated at seven pediatric oncology centers in the Netherlands.  The study focused on identifying patients that had received platinum agents without cranial irradiation since no previous studies have looked at ototoxicity outcomes in this population.  Risk factors evaluated for the development of hearing impairment included the impact of co-medications, type of platinum agent (cisplatin or carboplatin), and cumulative dose received.

Learn More Button

Article Categories: All News, PR Stories

Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on childhood cancer by discovering, developing, and disseminating new scientific knowledge. Our mission consists of three key areas — research, clinical, and education.

Stay connected with the Greehey CCRI on Facebook, Twitter, LinkedIn, and Instagram.